尋常性天疱瘡の世界市場規模、シェア、トレンド分析レポート
Market Size in USD Billion
CAGR :
% 
USD
419.49 Billion
USD
809.71 Billion
2024
2032
 予測期間 |
2025 –2032 |
 市場規模（基準年） |
USD 419.49 Billion |
 Market Size (Forecast Year) |
USD 809.71 Billion |
 CAGR |
% |
| Major Markets Players |
|
尋常性天疱瘡の世界市場：診断と治療（診断と治療）、人口タイプ（小児、成人、高齢者）、エンドユーザー（病院、専門クリニック、研究機関、その他）、流通チャネル（病院薬局、小売薬局、オンライン薬局）によるセグメンテーション - 2032年までの業界動向と予測
尋常性天疱瘡の市場規模
- 世界の尋常性天疱瘡市場規模は2024年に4億1,949万米ドルと評価され、予測期間中に8.7%のCAGRで成長し、2032年には8億971万米ドル に達すると予想されています 。
- 市場の成長は、尋常性天疱瘡の罹患率の上昇、自己免疫性皮膚疾患に関する意識の高まり、診断技術の進歩、効果的な治療オプションの研究開発への投資の増加によって主に促進されています。
- さらに、医療インフラの改善、先進治療への患者のアクセス向上、政府の支援策、尋常性天疱瘡をより効果的に管理するための生物学的製剤や標的治療への注目の高まりにより、市場は継続的な拡大が見込まれています。
尋常性天疱瘡市場分析
- 市場は、尋常性天疱瘡の発生率の上昇、自己免疫疾患に対する意識の高まり、生物学的療法の進歩によって牽引されており、効果的な治療オプションの需要の増加と患者の転帰の改善が世界中で起こっています。
- 市場の成長に影響を与える主な要因としては、医療インフラの拡大、医療費の増加、希少疾患研究に対する政府の支援、尋常性天疱瘡の管理をターゲットとした新規治療薬に焦点を当てた臨床試験の継続などが挙げられます。
- 北米は、高度な医療インフラ、患者の高い意識、活発な研究開発活動、生物学的療法の広範な利用可能性、希少疾患治療を促進する強力な政府の取り組みに支えられ、2025年には尋常性天疱瘡市場の45.93%の収益シェアを占めると予想されています。
- アジア太平洋地域は、医療投資の増加、患者数の増加、意識の高まり、診断施設の改善、新興経済国における高度な治療へのアクセスの拡大により、予測期間中に尋常性天疱瘡市場で最も急速に成長する地域になると予想されています。
- 治療セグメントは、生物学的療法の需要増加、自己免疫疾患の罹患率上昇、治療選択肢の進歩、および効果的で標的を絞った治療に対する患者の嗜好の高まりにより、2025年には尋常性天疱瘡市場の66.33%のシェアを占めると予想されています。
レポートの範囲と尋常性天疱瘡市場のセグメンテーション
|
属性 |
尋常性天疱瘡の主要市場洞察 |
|
対象セグメント |
|
|
対象国 |
アジア太平洋
北米
ヨーロッパ
南アメリカ
中東およびアフリカ
|
|
主要な市場プレーヤー |
|
|
市場機会 |
|
|
付加価値データ情報セット |
Data Bridge Market Research がまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、専門家による詳細な分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。 |
尋常性天疱瘡の市場動向
「自己免疫疾患の有病率の上昇」
- 自己免疫疾患の発生率の増加により患者基盤が拡大し、診断、治療、医療サービスに対する需要が高まり、世界的な市場成長が大きく促進されています。
- 市場関係者は、自己免疫疾患の負担増大に対応して、革新的な生物学的治療薬や標的治療薬を開発するために、研究開発に多額の投資を行っている。
- 意識の高まりと診断能力の向上により早期発見が促進され、治療の採用が増加し、市場全体の規模が拡大しています。
- 拡大する自己免疫疾患市場は製薬会社や政府からの多額の投資を引きつけ、市場競争力を高めるインフラや新製品の発売を支援している。
- 新興経済国における罹患率の上昇は新たな成長機会を生み出し、これらの地域での医療アクセスの改善と医療費の増加を通じて市場拡大を促します。
尋常性天疱瘡の市場動向
ドライバ
「尋常性天疱瘡の新たな治療選択肢」
- 従来のコルチコステロイドをベースとした治療法は効果的である一方で、重大な副作用と長期的な健康リスクを伴う。そのため、より安全で標的を絞った代替療法への強い需要が生じている。生物学的療法、特にリツキシマブなどの抗CD20モノクローナル抗体は、寛解率の向上とステロイドの必要性の低減という点で大きな期待が寄せられている。
- 例えば、2022年にFrontiers in Medicineに掲載された論文によると、免疫療法は疾患の予防または治療に有望であることが示されています。研究では天疱瘡におけるT細胞の重要性が示されており、Dsg3特異的CD4+ T細胞の機能は、界面皮膚炎とPVの表現型を誘導することで動物モデルで見事に実証されています。
- 制御性T細胞（Treg）の欠陥も、抗Dsg3自己抗体の産生を調節することで、天疱瘡の発症に寄与している可能性があります。体液性自己免疫の主な原因は、自己反応性T細胞とB細胞の相互作用であることが示されています。その結果、天疱瘡の免疫機構に関与するT細胞とB細胞の免疫軸が、天疱瘡患者の主要な治療標的となっています。
- さらに、新生児Fc受容体（FcRn）阻害剤やブルトン型チロシンキナーゼ（BTK）阻害剤といった新たなパイプライン候補薬が臨床試験を進めており、有効性と患者の安全性のさらなる向上を目指しています。これらの革新的なアプローチは治療選択肢を拡大し、製薬会社からの多額の投資を引きつけています。
- 主要市場における規制当局の承認、疾患に対する意識の高まり、そして生物学的製剤に対する医師の受容度の向上により、市場浸透はさらに加速しています。研究が進むにつれて、これらの新興治療法は治療環境を一変させ、長期的な市場成長を維持することが期待されます。
- 尋常性天疱瘡治療は、生物学的製剤と精密医療の進展によって、極めて大きな変革期を迎えています。より安全で効果的な治療法への需要が高まるにつれ、世界市場は大幅に拡大すると予想されています。FcRn阻害剤やB細胞標的療法といった革新的な治療法は、患者さんに新たな希望をもたらし、製薬会社には新たな収益源をもたらします。
抑制/挑戦
「尋常性天疱瘡の薬剤承認に関する厳格な規制ガイドライン」
- 厳格な規制ガイドラインとは、米国FDA、EMAなどの世界的な保健当局が医薬品の開発、承認、商業化に関して定める厳格な基準を指します。尋常性天疱瘡（PV）の場合、疾患の希少性と治療の複雑さから、これらの規制は極めて重要です。
- 例えば、2024年11月、オックスフォード大学出版局の記事では、米国FDAやEMAが概説したような厳格な規制ガイドラインにより、尋常性天疱瘡の治療法は安全性と有効性を確認するための厳格な臨床試験を受けることが保証されていることが強調されました。
- これらの措置は患者の安全にとって不可欠ですが、新しい治療法の承認と提供を遅らせる可能性があります。例えば、FDAの21 CFR 312規制やEMAのヒト用医薬品委員会（CHMP）のガイドラインでは、新しい治療法の承認前に広範なフェーズ試験が必要とされており、有望な治療法への患者のアクセスが制限される可能性があります。この徹底したプロセスは、患者を保護する一方で、その間の治療選択肢を制限する可能性があります。
- 厳格な規制ガイドラインは患者の安全確保に不可欠である一方で、世界の尋常性天疱瘡市場においては課題と機会の両方をもたらします。一方では、安全で効果的な治療法のみが患者に届くことを保証し、承認された治療法への信頼を高めます。他方では、長期にわたる承認プロセスと高いコンプライアンスコストがイノベーションを遅らせ、市場へのアクセスを制限する可能性があります。
尋常性天疱瘡の市場範囲
市場は、診断と治療、人口タイプ、エンドユーザー、流通チャネルに基づいてセグメント化されています。
- 診断と治療
診断と治療に基づき、市場は診断と治療の2つに区分されます。2025年には、診断技術の進歩、早期かつ正確な診断への需要の高まり、認知度の高まり、そして尋常性天疱瘡の効果的な管理のための革新的な診断ツールの導入拡大により、治療分野が市場シェアの66.33%を占め、市場を牽引すると予想されます。
治療セグメントは、診断ツールの技術的進歩、尋常性天疱瘡の罹患率の増加、早期発見に関する意識の高まり、医療インフラの拡大、非侵襲的で正確な診断方法の世界的な採用拡大により、2025年から2032年にかけて9.0%という最も高い成長率を記録すると予想されています。
- 人口タイプ別
人口タイプに基づいて、市場は小児、成人、高齢者の3つに分類されます。2025年には、小児における尋常性天疱瘡の診断件数の増加、介護者の意識向上、小児特有の治療法の進歩、早期介入への注目の高まり、そして先進地域と新興地域の両方における小児の医療アクセスの向上により、成人セグメントが最大の市場収益シェアを占めると予想されます。
成人セグメントは、小児の自己免疫疾患の罹患率の増加、親の意識の高まり、小児に優しい治療法の進歩、診断精度の向上、先進国市場と新興国市場の両方における小児医療に重点を置いた医療インフラの拡大により、2025年から2032年にかけて9.0%という最も高いCAGRを達成すると予想されています。
- エンドユーザー別
エンドユーザーに基づいて、市場は病院、専門クリニック、研究機関、その他に分類されます。病院セグメントは、高度な医療施設、専門医療従事者の確保、包括的な治療オプション、患者数の増加、革新的な治療法の導入拡大、そして尋常性天疱瘡の効果的な管理のための病院インフラを支援する政府資金の増加により、2025年には最大の市場収益シェアを獲得しました。
病院セグメントは、設備の整ったインフラ、多分野にわたる専門家の存在、高度な診断および治療施設、病院での治療に対する患者の嗜好の増加、天疱瘡などの複雑な自己免疫疾患のより適切な管理を支援する医療投資の拡大などの理由から、2025年から2032年にかけて最も速いCAGRを達成すると予想されています。
- 流通チャネル別
流通チャネルに基づいて、市場は病院薬局、小売薬局、オンライン薬局に分類されます。病院薬局セグメントは、処方薬への直接アクセス、病院との強力なパートナーシップ、患者からの信頼の向上、専門医薬品の入手可能性、合理化されたサプライチェーン、そして尋常性天疱瘡患者への包括的なケアとカウンセリングの提供能力に牽引され、2025年には最大の市場収益シェアを占めました。
病院薬局セグメントは、入院数の増加、専門医薬品の需要の高まり、サプライチェーンの効率性の向上、尋常性天疱瘡患者に対する院内投薬の選好の高まりにより、2025年から2032年にかけて最も速いCAGRを示すことが予想されています。
尋常性天疱瘡市場の地域分析
- 北米は、高度な医療インフラ、患者の高い意識、活発な研究開発活動、生物学的療法の広範な利用可能性、希少疾患治療を促進する強力な政府の取り組みに支えられ、2025年には尋常性天疱瘡市場の45.93%の収益シェアを占めると予想されています。
- 北米の優位性は、多額の医療投資、確立された製薬業界、包括的な保険適用によって強化されており、患者が最先端の尋常性天疱瘡の治療と診断にアクセスできるようにしています。
- さらに、政府機関、研究機関、バイオテクノロジー企業間の積極的な協力により、革新と新しい治療法の承認が加速され、この地域の市場成長がさらに促進されます。
米国における尋常性天疱瘡市場の洞察
米国は、先進的な医療インフラ、認知度の高まり、自己免疫疾患の有病率の上昇、そして新規治療法の導入拡大により、2025年には北米地域最大の市場収益シェア（82.78%）を占めると予想されています。さらに、強力な政府支援と継続的な研究も、この地域の市場成長を後押ししています。
カナダにおける尋常性天疱瘡市場の洞察
カナダは、バイオメディカル研究への投資増加、尋常性天疱瘡の発生率上昇、先進的な医療施設、患者意識の高まり、そして革新的な治療法の導入を背景に、2025年から2032年にかけて8.2%の年平均成長率（CAGR）を達成すると予想されています。強力な規制支援は、この地域における市場拡大をさらに加速させるでしょう。
ヨーロッパにおける尋常性天疱瘡市場の洞察
欧州は、確立された医療制度、希少自己免疫疾患への高い認知度、先進治療へのアクセス向上、そして大手製薬企業の強力なプレゼンスを背景に、2025年には25.18%という大きな市場シェアを占めると予想されています。また、支援的な規制政策と研究活動の活発化も、この地域の市場における高い地位に貢献しています。
ドイツにおける尋常性天疱瘡市場の洞察
ドイツは、堅牢な医療インフラ、高い診断率、尋常性天疱瘡に対する認識の高まり、自己免疫疾患の研究と治療開発に積極的に関与する製薬企業の強力な存在により、2025年にはヨーロッパ地域内で26.12%という最大の収益シェアを占めると予想されています。
英国における尋常性天疱瘡市場の洞察
英国市場は、尋常性天疱瘡に対する認知度の高まり、医療費の増加、早期診断への取り組み、そして先進的な治療法の導入により、年平均成長率（CAGR）8.9%で成長すると予想されています。政府の支援と活発な臨床研究も、英国における市場環境の拡大に貢献しています。
アジア太平洋地域の尋常性天疱瘡市場に関する洞察
アジア太平洋地域は、患者数の増加、医療インフラの改善、自己免疫疾患への意識の高まり、先進治療へのアクセス向上を背景に、2025年には世界の尋常性天疱瘡市場において大きなシェアを獲得すると予想されています。医療への投資拡大と政府の支援策も、この地域の市場成長をさらに加速させています。
中国における尋常性天疱瘡市場の洞察
中国は、膨大な患者基盤、医療インフラの急速な改善、政府の医療費支出の増加、そして希少自己免疫疾患に対する認知度の高まりを背景に、2025年にはアジア太平洋市場をリードすると予想されています。さらに、臨床研究活動の拡大と革新的な治療法の導入も、同国の市場リーダーシップに大きく貢献しています。
インドにおける尋常性天疱瘡市場の洞察
インドでは、疾患意識の高まり、医療費の増加、診断能力の向上、先進治療へのアクセス拡大により、尋常性天疱瘡市場が着実に成長すると予想されています。希少疾患管理に対する政府の支援と研究開発への重点化は、インド全土における市場拡大をさらに加速させています。
尋常性天疱瘡の市場シェア
尋常性天疱瘡市場は、主に、以下を含む定評のある企業によって牽引されています。
- メルク社（米国）
- サノフィ（フランス）
- リジェネロン・ファーマシューティカルズ社（米国）
- ジョンソン・エンド・ジョンソン・サービス社（米国）
- アストラゼネカ（英国）
- グリフォルスSA（スペイン）
- ザイダスグループ（インド）
- F. ホフマン・ラ・ロシュ社（スイス）
- GSK plc.（英国）
- ベーリンガーインゲルハイムインターナショナルGmbH（ドイツ）
- セルトリオン（韓国）
- リリー（米国）
- ファイザー社（米国）
- アッヴィ社（米国）
- フレゼニウス・カビAG（ドイツ）
- Rakshit Drugs Private Limited (インド)
- アムジェン社（米国）
- ノバルティスAG（スイス）
- テバ製薬工業株式会社（イスラエル）
- アルティバ・バイオセラピューティクス社（米国）
- カバレッタ・バイオ社（米国）
- インサイト（米国）
- CSL（オーストラリア）
- バクスター（米国）
- アコード・ヘルスケア（英国）
- 大雄製薬株式会社(韓国)
- SUNPHARMA.NS（インド）
- オクタファーマAG（スイス）
- シプラヘルス社（インド）
- BioXpress Therapeutics SA（スイス）
尋常性天疱瘡の世界市場の最新動向
- 2021年9月、第3相PEGASUS試験において、稀な自己免疫性皮膚疾患である中等度から重度の尋常性天疱瘡または落葉状天疱瘡の成人患者を対象に、リルザブルチニブを評価しました。リルザブルチニブは新たな懸念事項なく一貫した安全性プロファイルを示しましたが、主要評価項目および主要な副次評価項目は達成されませんでした。主要評価項目である低用量コルチコステロイド投与による29週から37週までの完全寛解は、プラセボとの有意差はありませんでした。これは、天疱瘡に対するBTK阻害剤のプラセボ対照試験としては初めてのものであり、この複雑な疾患の治療の難しさを浮き彫りにしました。
- 2025年2月、リジェネロン社とサノフィ社は、希少自己免疫性水疱性疾患である水疱性類天疱瘡（BP）の成人患者治療薬として、デュピクセントの生物学的製剤承認追加申請（sBLA）を米国食品医薬品局（FDA）に提出しました。この申請は、ADEPT第2/3相試験の良好なデータに基づいており、デュピクセントがBP患者の疾患寛解率を有意に改善し、重症度を軽減し、掻痒を軽減することが示されました。FDAは申請を優先審査の対象として受理し、2025年6月20日までに決定が下される予定です。この提携は、BP患者に新たな治療選択肢を提供し、自己免疫性水疱性疾患におけるデュピクセントの役割をさらに拡大することを目指しています。
- 2025年3月、リジェネロン社は水疱性類天疱瘡（BP）における成功に続き、尋常性天疱瘡（PV）に対するデュピクセントの可能性に関する研究を拡大しました。水疱性類天疱瘡とPVは共にタイプ2炎症メカニズムを共有しており、デュピクセントはPV治療の有望な候補薬として位置付けられています。現在進行中の研究ではPVにおけるデュピクセントの有効性を評価しており、初期結果では潜在的なベネフィットが示唆されています。この探索は、PV患者に新たな治療選択肢を提供することを目指しており、自己免疫性水疱性疾患におけるデュピクセントの適用をさらに拡大します。
- 2025 年 4 月、メルク社は、デラウェア州ウィルミントンに 470,000 平方フィートに及ぶ 10 億米ドルの投資による最先端のバイオ医薬品研究センターを建設すると発表しました。
- 2024年9月、サノフィの生物学的製剤デュピクセントは、希少かつ生命を脅かす自己免疫性皮膚疾患である水疱性類天疱瘡（BP）と尋常性天疱瘡（PV）の両疾患において、疾患寛解と症状の有意な改善を示しました。ADEPT第3相試験では、デュピクセントを投与されたBP患者は、プラセボを投与された患者と比較して、持続的な寛解を達成した患者数が5倍に増加しました。この試験は主要評価項目とすべての主要な副次評価項目を達成し、強力なステロイド節減効果を示しました。デュピクセントは、米国およびEUにおいて、規制当局の承認を待って、BPおよびPVに対する初の標的治療薬となる見込みです。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.3 PATENT ANALYSIS
4.3.1 PATIENT FLOW DIAGRAM
4.3.2 KEY PRICING STRATEGIES
4.3.3 FUTURE THERAPIES
4.3.4 KEY PATIENT ENROLLMENT STRATEGIES
4.4 GLOBAL CLINICAL TRIAL MARKET FOR PEMPHIGUS VULGARIS MARKET
4.5 SUPPLY CHAIN ECOSYSTEM
4.6 HEALTHCARE TARIFFS & IMPACT ON THE MARKET: GLOBAL PEMPHIGUS VULGARIS MARKET
4.7 EPIDEMIOLOGY: GLOBAL PEMPHIGUS VULGARIS MARKET
4.7.1 INCIDENCE BY GENDER
4.7.2 TREATMENT RATE
4.7.3 MORTALITY RATE
4.7.4 PATIENT TREATMENT SUCCESS RATES
5 GLOBAL PEMPHIGUS VULGARIS MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS
6.1.2 RISING PREVALENCE OF AUTOIMMUNE DISORDERS
6.1.3 GROWING AWARENESS OF PEMPHIGUS VULGARIS
6.1.4 GROWING ADOPTION OF IMMUNOSUPPRESSIVE TREATMENTS
6.2 RESTRAINTS
6.2.1 STRINGENT REGULATORY GUIDELINES FOR PEMPHIGUS VULGARIS DRUG APPROVAL
6.2.2 HIGH TREATMENT COSTS FOR PEMPHIGUS VULGARIS THERAPIES
6.3 OPPORTUNITIES
6.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE
6.3.2 INCREASING HEALTHCARE FACILITIES
6.3.3 RISING ADOPTION OF DIGITAL HEALTH TECHNOLOGIES FOR PEMPHIGUS VULGARIS TREATMENT MANAGEMENT
6.4 CHALLENGES
6.4.1 RISING CONCERNS OVER ADVERSE EFFECTS OF PEMPHIGUS VULGARIS MEDICATIONS
6.4.2 LACK OF REIMBURSEMENT AND COVERAGE POLICIES
7 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT
7.1 OVERVIEW
7.2 TREATMENT
7.3 DIAGNOSIS
8 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE
8.1 OVERVIEW
8.2 ADULTS
8.3 GERIATRIC
8.4 PEDIATRIC
9 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 RESEARCH INSTITUTES
9.5 OTHERS
10 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITALS PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY
11 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 EUROPE
11.3.1 GERMANY
11.3.2 U.K.
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 SWITZERLAND
11.3.7 TURKEY
11.3.8 RUSSIA
11.3.9 BELGIUM
11.3.10 NETHERLANDS
11.3.11 DENMARK
11.3.12 NORWAY
11.3.13 FINLAND
11.3.14 POLAND
11.3.15 SWEDEN
11.3.16 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 INDIA
11.4.3 SOUTH KOREA
11.4.4 MALAYSIA
11.4.5 JAPAN
11.4.6 AUSTRALIA
11.4.7 SINGAPORE
11.4.8 THAILAND
11.4.9 INDONESIA
11.4.10 NEW ZEALAND
11.4.11 TAIWAN
11.4.12 PHILIPPINES
11.4.13 HONG KONG
11.4.14 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 ARGENTINA
11.5.3 COLOMBIA
11.5.4 PERU
11.5.5 URUGUAY
11.5.6 ECUADOR
11.5.7 PARAGUAY
11.5.8 VENEZUELA
11.5.9 BOLIVIA
11.5.10 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SAUDI ARABIA
11.6.2 EGYPT
11.6.3 U.A.E.
11.6.4 SOUTH AFRICA
11.6.5 ISRAEL
11.6.6 BAHRAIN
11.6.7 KUWAIT
11.6.8 OMAN
11.6.9 QATAR
11.6.10 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MERCK AND CO. INC.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 SANOFI
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 REGENERON PHARMACEUTICALS INC.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 JOHNSON & JOHNSON SERVICES, INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 ASTRAZENECA
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 ABBVIE INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ACCORD HEALTHCARE
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENT
14.8 AMGEN INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ARTIVA BIOTHERAPEUTICS, INC.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PIPELINE PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 BAXTER
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 BIOXPRESS THERAPEUTICS SA
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 CABALETTA BIO INC.
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
14.14 CIPLA HEALTH LTD
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 CELLTRION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.16 CSL
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENT
14.17 DAEWOONG PHARMACEUTICAL CO.,LTD.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 F. HOFFMANN- LA ROCHE LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT/NEWS
14.19 FRESENIUS KABI AG
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENT
14.2 GSK PLC
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENT
14.21 GRIFOLS, S.A.
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
14.22 INCYTE
14.22.1 COMPANY SNAPSHOT
14.22.2 REVENUE ANALYSIS
14.22.3 PRODUCT PORTFOLIO
14.22.4 RECENT DEVELOPMENT
14.23 NOVARTIS AG
14.23.1 COMPANY SNAPSHOT
14.23.2 REVENUE ANALYSIS
14.23.3 PRODUCT PORTFOLIO
14.23.4 RECENT DEVELOPMENT
14.24 LILLY
14.24.1 COMPANY SNAPSHOT
14.24.2 REVENUE ANALYSIS
14.24.3 PRODUCT PORTFOLIO
14.24.4 RECENT DEVELOPMENT
14.25 OCTAPHARMA AG
14.25.1 COMPANY SNAPSHOT
14.25.2 REVENUE ANALYSIS
14.25.3 PRODUCT PORTFOLIO
14.25.4 RECENT DEVELOPMENT/NEWS
14.26 PFIZER INC.
14.26.1 COMPANY SNAPSHOT
14.26.2 REVENUE ANALYSIS
14.26.3 PRODUCT PORTFOLIO
14.26.4 RECENT DEVELOPMENT
14.27 RAKSHIT DRUGS PVT. LTD
14.27.1 COMPANY SNAPSHOT
14.27.2 PRODUCT PORTFOLIO
14.27.3 RECENT DEVELOPMENT
14.28 SUN PHARMACEUTICALS INDUSTRIES LTD.
14.28.1 COMPANY SNAPSHOT
14.28.2 REVENUE ANALYSIS
14.28.3 PRODUCT PORTFOLIO
14.28.4 RECENT DEVELOPMENT
14.29 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.29.1 COMPANY SNAPSHOT
14.29.2 REVENUE ANALYSIS
14.29.3 PRODUCT PORTFOLIO
14.29.4 RECENT DEVELOPMENT
14.3 ZYDUS GROUP
14.30.1 COMPANY SNAPSHOT
14.30.2 REVENUE ANALYSIS
14.30.3 PRODUCT PORTFOLIO
14.30.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
表のリスト
TABLE 1 GLOBAL PEMPHIGUS VULGARIS MARKET, PATENT ANALYSIS
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL PEMPHIGUS VULGARIS MARKET
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE GLOBAL PEMPHIGUS VULGARIS MARKET
TABLE 4 SURVIVAL RATES IN PEMPHIGUS VULGARIS
TABLE 5 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 6 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2028-2032 (USD MILLION)
TABLE 7 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 8 GLOBAL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 9 GLOBAL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 10 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 11 GLOBAL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 12 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 13 GLOBAL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 14 GLOBAL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 15 GLOBAL ADULTS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 16 GLOBAL GERIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 17 GLOBAL PEDIATRIC IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 18 GLOBAL PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 19 GLOBAL HOSPITALS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 20 GLOBAL SPECIALTY CLINICS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 21 GLOBAL RESEARCH INSTITUTES IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 22 GLOBAL OTHERS IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 23 GLOBAL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 24 GLOBAL HOSPITALS PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 25 GLOBAL RETAIL PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 26 GLOBAL ONLINE PHARMACY IN PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 27 GLOBAL PEMPHIGUS VULGARIS MARKET, BY REGION, 2018-2032 (USD MILLION)
TABLE 28 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 30 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 31 NORTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 32 NORTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 33 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 34 NORTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 35 NORTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 36 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 37 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 39 U.S. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 40 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 41 U.S. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 42 U.S. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 43 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 44 U.S. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 45 U.S. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 46 U.S. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 47 U.S. PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 48 U.S. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 49 CANADA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 50 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 51 CANADA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 52 CANADA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 53 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 54 CANADA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 55 CANADA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 56 CANADA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 57 CANADA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 58 CANADA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 59 MEXICO PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 60 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 61 MEXICO STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 62 MEXICO ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 63 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 64 MEXICO TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 65 MEXICO DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 66 MEXICO PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 67 MEXICO PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 68 MEXICO PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 69 EUROPE PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 71 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 72 EUROPE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 73 EUROPE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 74 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 75 EUROPE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 76 EUROPE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 77 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 78 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 79 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 80 GERMANY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 81 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 82 GERMANY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 83 GERMANY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 84 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 85 GERMANY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 86 GERMANY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 87 GERMANY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 88 GERMANY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 89 GERMANY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 90 U.K. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 91 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 92 U.K. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 93 U.K. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 94 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 95 U.K. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 96 U.K. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 97 U.K. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 98 U.K. PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 99 U.K. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 100 FRANCE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 101 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 102 FRANCE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 103 FRANCE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 104 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 105 FRANCE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 106 FRANCE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 107 FRANCE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 108 FRANCE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 109 FRANCE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 110 ITALY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 111 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 112 ITALY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 113 ITALY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 114 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 115 ITALY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 116 ITALY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 117 ITALY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 118 ITALY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 119 ITALY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 120 SPAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 121 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 122 SPAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 123 SPAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 124 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 125 SPAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 126 SPAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 127 SPAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 128 SPAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 129 SPAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 130 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 131 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 132 SWITZERLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 133 SWITZERLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 134 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 135 SWITZERLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 136 SWITZERLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 137 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 138 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 139 SWITZERLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 140 TURKEY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 141 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 142 TURKEY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 143 TURKEY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 144 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 145 TURKEY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 146 TURKEY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 147 TURKEY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 148 TURKEY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 149 TURKEY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 150 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 151 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 152 RUSSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 153 RUSSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 154 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 155 RUSSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 156 RUSSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 157 RUSSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 158 RUSSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 159 RUSSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 160 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 161 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 162 BELGIUM STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 163 BELGIUM ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 164 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 165 BELGIUM TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 166 BELGIUM DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 167 BELGIUM PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 168 BELGIUM PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 169 BELGIUM PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 170 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 171 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 172 NETHERLANDS STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 173 NETHERLANDS ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 174 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 175 NETHERLANDS TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 176 NETHERLANDS DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 177 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 178 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 179 NETHERLANDS PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 180 DENMARK PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 181 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 182 DENMARK STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 183 DENMARK ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 184 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 185 DENMARK TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 186 DENMARK DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 187 DENMARK PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 188 DENMARK PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 189 DENMARK PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 190 NORWAY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 191 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 192 NORWAY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 193 NORWAY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 194 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 195 NORWAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 196 NORWAY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 197 NORWAY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 198 NORWAY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 199 NORWAY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 200 FINLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 201 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 202 FINLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 203 FINLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 204 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 205 FINLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 206 FINLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 207 FINLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 208 FINLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 209 FINLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 210 POLAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 211 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 212 POLAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 213 POLAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 214 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 215 POLAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 216 POLAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 217 POLAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 218 POLAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 219 POLAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 220 SWEDEN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 221 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 222 SWEDEN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 223 SWEDEN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 224 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 225 SWEDEN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 226 SWEDEN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 227 SWEDEN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 228 SWEDEN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 229 SWEDEN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 230 REST OF EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 231 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 232 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 233 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 234 ASIA-PACIFIC STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 235 ASIA-PACIFIC ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 236 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 237 ASIA-PACIFIC TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 238 ASIA-PACIFIC DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 239 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 240 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 241 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 242 CHINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 243 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 244 CHINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 245 CHINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 246 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 247 CHINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 248 CHINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 249 CHINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 250 CHINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 251 CHINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 252 INDIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 253 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 254 INDIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 255 INDIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 256 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 257 INDIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 258 INDIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 259 INDIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 260 INDIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 261 INDIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 262 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 263 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 264 SOUTH KOREA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 265 SOUTH KOREA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 266 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 267 SOUTH KOREA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 268 SOUTH KOREA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 269 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 270 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 271 SOUTH KOREA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 272 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 273 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 274 MALAYSIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 275 MALAYSIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 276 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 277 MALAYSIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 278 MALAYSIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 279 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 280 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 281 MALAYSIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 282 JAPAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 283 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 284 JAPAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 285 JAPAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 286 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 287 JAPAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 288 JAPAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 289 JAPAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 290 JAPAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 291 JAPAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 292 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 293 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 294 AUSTRALIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 295 AUSTRALIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 296 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 297 AUSTRALIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 298 AUSTRALIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 299 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 300 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 301 AUSTRALIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 302 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 303 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 304 SINGAPORE STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 305 SINGAPORE ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 306 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 307 SINGAPORE TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 308 SINGAPORE DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 309 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 310 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 311 SINGAPORE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 312 THAILAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 313 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 314 THAILAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 315 THAILAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 316 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 317 THAILAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 318 THAILAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 319 THAILAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 320 THAILAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 321 THAILAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 322 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 323 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 324 INDONESIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 325 INDONESIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 326 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 327 INDONESIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 328 INDONESIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 329 INDONESIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 330 INDONESIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 331 INDONESIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 332 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 333 NEW ZEALAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 334 NEW ZEALAND STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 335 NEW ZEALAND ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 336 NEW ZEALAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 337 NEW ZEALAND TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 338 NEW ZEALAND DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 339 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 340 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 341 NEW ZEALAND PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 342 TAIWAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 343 TAIWAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 344 TAIWAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 345 TAIWAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 346 TAIWAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 347 TAIWAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 348 TAIWAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 349 TAIWAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 350 TAIWAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 351 TAIWAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 352 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 353 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 354 PHILIPPINES STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 355 PHILIPPINES ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 356 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 357 PHILIPPINES TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 358 PHILIPPINES DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 359 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 360 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 361 PHILIPPINES PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 362 HONG KONG PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 363 HONG KONG TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 364 HONG KONG STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 365 HONG KONG ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 366 HONG KONG TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 367 HONG KONG TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 368 HONG KONG DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 369 HONG KONG PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 370 HONG KONG PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 371 HONG KONG PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 372 REST OF ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 373 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 374 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 375 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 376 SOUTH AMERICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 377 SOUTH AMERICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 378 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 379 SOUTH AMERICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 380 SOUTH AMERICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 381 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 382 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 383 SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 384 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 385 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 386 BRAZIL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 387 BRAZIL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 388 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 389 BRAZIL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 390 BRAZIL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 391 BRAZIL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 392 BRAZIL PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 393 BRAZIL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 394 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 395 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 396 ARGENTINA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 397 ARGENTINA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 398 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 399 ARGENTINA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 400 ARGENTINA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 401 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 402 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 403 ARGENTINA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 404 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 405 COLOMBIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 406 COLOMBIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 407 COLOMBIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 408 COLOMBIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 409 COLOMBIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 410 COLOMBIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 411 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 412 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 413 COLOMBIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 414 PERU PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 415 PERU TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 416 PERU STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 417 PERU ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 418 PERU TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 419 PERU TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 420 PERU DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 421 PERU PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 422 PERU PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 423 PERU PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 424 URUGUAY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 425 URUGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 426 URUGUAY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 427 URUGUAY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 428 URUGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 429 URUGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 430 URUGUAY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 431 URUGUAY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 432 URUGUAY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 433 URUGUAY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 434 ECUADOR PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 435 ECUADOR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 436 ECUADOR STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 437 ECUADOR ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 438 ECUADOR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 439 ECUADOR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 440 ECUADOR DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 441 ECUADOR PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 442 ECUADOR PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 443 ECUADOR PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 444 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 445 PARAGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 446 PARAGUAY STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 447 PARAGUAY ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 448 PARAGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 449 PARAGUAY TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 450 PARAGUAY DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 451 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 452 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 453 PARAGUAY PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 454 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 455 VENEZUELA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 456 VENEZUELA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 457 VENEZUELA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 458 VENEZUELA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 459 VENEZUELA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 460 VENEZUELA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 461 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 462 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 463 VENEZUELA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 464 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 465 BOLIVIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 466 BOLIVIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 467 BOLIVIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 468 BOLIVIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 469 BOLIVIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 470 BOLIVIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 471 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 472 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 473 BOLIVIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 474 REST OF SOUTH AMERICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 475 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 476 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 477 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 478 MIDDLE EAST AND AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 479 MIDDLE EAST AND AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 480 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 481 MIDDLE EAST AND AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 482 MIDDLE EAST AND AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 483 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 484 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 485 MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 486 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 487 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 488 SAUDI ARABIA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 489 SAUDI ARABIA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 490 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 491 SAUDI ARABIA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 492 SAUDI ARABIA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 493 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 494 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 495 SAUDI ARABIA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 496 EGYPT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 497 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 498 EGYPT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 499 EGYPT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 500 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 501 EGYPT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 502 EGYPT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 503 EGYPT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 504 EGYPT PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 505 EGYPT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 506 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 507 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 508 U.A.E. STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 509 U.A.E. ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 510 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 511 U.A.E. TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 512 U.A.E. DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 513 U.A.E. PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 514 U.A.E. PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 515 U.A.E. PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 516 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 517 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 518 SOUTH AFRICA STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 519 SOUTH AFRICA ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 520 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 521 SOUTH AFRICA TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 522 SOUTH AFRICA DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 523 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 524 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 525 SOUTH AFRICA PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 526 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 527 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 528 ISRAEL STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 529 ISRAEL ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 530 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 531 ISRAEL TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 532 ISRAEL DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 533 ISRAEL PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 534 ISRAEL PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 535 ISRAEL PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 536 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 537 BAHRAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 538 BAHRAIN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 539 BAHRAIN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 540 BAHRAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 541 BAHRAIN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 542 BAHRAIN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 543 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 544 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 545 BAHRAIN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 546 KUWAIT PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 547 KUWAIT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 548 KUWAIT STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 549 KUWAIT ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 550 KUWAIT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 551 KUWAIT TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 552 KUWAIT DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 553 KUWAIT PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 554 KUWAIT PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 555 KUWAIT PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 556 OMAN PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 557 OMAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 558 OMAN STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 559 OMAN ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 560 OMAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 561 OMAN TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 562 OMAN DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 563 OMAN PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 564 OMAN PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 565 OMAN PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 566 QATAR PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
TABLE 567 QATAR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 568 QATAR STEROID-SPARING IMMUNOSUPPRESSANT DRUGS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 569 QATAR ANTI-INFLAMMATORY AGENTS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 570 QATAR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 571 QATAR TREATMENT IN PEMPHIGUS VULGARIS MARKET, BY DRUG TYPE, 2018-2032 (USD MILLION)
TABLE 572 QATAR DIAGNOSIS IN PEMPHIGUS VULGARIS MARKET, BY TYPE, 2018-2032 (USD MILLION)
TABLE 573 QATAR PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE, 2018-2032 (USD MILLION)
TABLE 574 QATAR PEMPHIGUS VULGARIS MARKET, BY END USER, 2018-2032 (USD MILLION)
TABLE 575 QATAR PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 576 REST OF MIDDLE EAST AND AFRICA PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD MILLION)
図表一覧
FIGURE 1 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION
FIGURE 2 GLOBAL PEMPHIGUS VULGARIS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL PEMPHIGUS VULGARIS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL PEMPHIGUS VULGARIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL PEMPHIGUS VULGARIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL PEMPHIGUS VULGARIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL PEMPHIGUS VULGARIS MARKET: END USER COVERAGE GRID
FIGURE 9 GLOBAL PEMPHIGUS VULGARIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL PEMPHIGUS VULGARIS MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 TWO SEGMENTS COMPRISE THE GLOBAL PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT, (2024)
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL PEMPHIGUS VULGARIS MARKET, AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 15 THE EMERGING TREATMENT OPTIONS FOR THE PEMPHIGUS VULGARIS IS EXPECTED TO DRIVE THE GROWTH OF THE GLOBAL PEMPHIGUS VULGARIS MARKET FROM 2025 TO 2032
FIGURE 16 DIAGNOSIS AND TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL PEMPHIGUS VULGARIS MARKET IN 2025 AND 2032
FIGURE 17 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR PEMPHIGUS VULGARIS MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 18 PATIENT FLOW DESCRIPTION OF PEMPHIGUS VULGARIS:-
FIGURE 19 DROC ANALYSIS
FIGURE 20 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2024
FIGURE 21 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD MILLION)
FIGURE 22 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)
FIGURE 23 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 24 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2024
FIGURE 25 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, 2025-2032 (USD MILLION)
FIGURE 26 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, CAGR (2025-2032)
FIGURE 27 GLOBAL PEMPHIGUS VULGARIS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 28 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2024
FIGURE 29 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, 2025-2032 (USD MILLION)
FIGURE 30 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, CAGR (2025-2032)
FIGURE 31 GLOBAL PEMPHIGUS VULGARIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 32 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 33 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
FIGURE 34 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 35 GLOBAL PEMPHIGUS VULGARIS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 36 GLOBAL PEMPHIGUS VULGARIS MARKET: SNAPSHOT (2024)
FIGURE 37 GLOBAL PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)
FIGURE 38 NORTH AMERICA PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)
FIGURE 39 EUROPE PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)
FIGURE 40 ASIA-PACIFIC PEMPHIGUS VULGARIS MARKET: COMPANY SHARE 2024 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
